Yonsei Med J.  2008 Apr;49(2):237-243. 10.3349/ymj.2008.49.2.237.

Factor VLeiden and Prothrombin G20210A Gene Polymorphisms in Patients with Coronary Artery Disease

• Ercan B
• Tamer L
• Sucu N
• Pekdemir H
• Camsari A
• Atik U

• KMID: 1084496
• DOI: http://doi.org/10.3349/ymj.2008.49.2.237

Abstract

PURPOSE
The precise molecular mechanisms culminating in coronary artery disease (CAD) are not well understood, despite a wealth of knowledge on predisposing risk factors and pathomechanisms. CAD and myocardial infarction (MI) are complex genetic diseases; neither the environment alone, nor a single gene, cause disease, rather, a mix of environmental and genetic factors lead to atherosclerosis of the coronary arteries. MATERIALS AND METHODS: In the present study, our aim was to investigate the roles of prothrombin G20210A mutation and Factor VLeiden mutation in atherosclerotic coronary artery disease. 287 subjects (106 control subjects, who were angiographically normal, and 181 angiographically documented coronary atherosclerotic patients who exhibited coronary artery narrowing to a degree of > or = 50%) were included in this study. The mutations were assessed with LightCycler Real-Time PCR mutation detection kits (Roche Diagnostics, GmbH, Germany). RESULTS: 6.6% of control subjects, and 6.1% of patients with (50% coronary artery narrowing were determined to have the Factor VLeiden heterozygote mutation. 6.6% of control subjects had the Prothrombin G20210A heterozygote mutation, while 7.7% of patients with (50% coronary artery narrowing had this mutation. The OR for Factor VLeiden was 1.52 (CI: 0.240-9.602) and for Prothrombin G20210A mutation, the OR was 1.415 (CI: 0.287-6.962). CONCLUSION: Although both the heterozygote Factor VLeiden and Prothrombin gene mutations were more frequent in patients with CAD than in control subjects, there was no statistical relationship found to exist between coronary artery disease and the Factor VLeiden and Prothrombin G20210A mutations.

Keyword

Coronary artery disease; Factor VLeiden; prothrombin G20210A gene

MeSH Terms

Aged
Coronary Artery Disease/*genetics
Factor V/*genetics
Female
Gene Frequency
Genotype
Humans
Male
Middle Aged
*Polymorphism, Single Nucleotide
Prothrombin/*genetics

Reference

1. Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000. 149:251–266.

2. Ardissino BY, Mannucci PM, Mertini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999. 94:46–51.

3. Ridker PM. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis. Thromb Haemost. 1997. 78:53–59.

4. Cushman M. Schechter GP, Hoffman R, Schrier SL, editors. Hemostatic risk factors for cardiovascular disease. Hematology. 1999. Washington. DC: American Society of Haematology.

5. Di Minno G, Grandone E, Margaglione M. Clinical relevance of polymorphic markers of arterial thrombosis. Thromb Haemost. 1997. 78:462–466.

6. Grant PJ. Polymorphisms of coagulation/fibrinolysis genes: gene environment interactions and vascular risk. Prostaglandins Leukot Essent Fatty Acids. 1997. 57:473–477.

7. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost. 1997. 78:523–526.

8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994. 369:64–67.

9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996. 88:3698–3703.

10. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997. 98:353–355.

11. Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol. 1997. 17:2875–2879.

12. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997. 78:1426–1429.

13. Arruda VR, Annichino-Bizzacchi JM, Gonçalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost. 1997. 78:1430–1433.

14. Watzke HH, Schüttrumpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res. 1997. 87:521–526.

15. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998. 91:3562–3565.

16. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997. 90:1747–1750.

17. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol. 1997. 17:2418–2422.

18. Corral J, Gonzalez-Conjero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol. 1997. 99:304–307.

19. Longstreth WT Jr, Rosendaal FR, Siscovic DS, Vos HL, Schwartz SM, Psaty BM, et al. Risk of stroke in young women and two prothrombotic mutations: factor VLeiden and Prothrombin gene variant (G20210A). Stroke. 1998. 29:577–580.

20. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in a coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet. 1995. 345:526.

21. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med. 1996. 239:221–226.

22. Rosendaal FK, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor VLeiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997. 89:2817–2821.

23. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996. 125:265–269.

24. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med. 1995. 332:912–917.

25. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis. 1995. 6:456–459.

26. Lerman A, Suwaidi JA, Velianou JL. L-Arginine: a novel therapy for coronary artery disease? Expert Opin Investig Drugs. 1999. 8:1785–1793.

27. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993. 362:801–809.

28. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994. 90:2126.

29. Farmer JA, Gotto AM Jr. Braunwa E, editor. Dyslipidemia and other risk factors for coronary artery disease. Heart disease. A textbook of cardiovascular medicine. 1997. 5th ed. Philadelphia, PA: W.B. Saunders.

30. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, et al. Synergistic effects of prothrombic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 1999. 93:2186–2190.

31. Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, et al. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation. 2001. 103:2436–2440.

32. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor VLeiden or prothrombin 20210A. Circulation. 1998. 97:1037–1041.

33. Burzotta F, Paciaroni K, De Stefano V, Chiusolo P, Manzoli A, Casorelli I, et al. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J. 2002. 23:26–30.

34. Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis FK, et al. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens. 2000. 13:61–65.

35. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999. 99:999–1004.

36. Çelik S, Ovali E, Baykan M, Uçar F, Erdöl C, Durmuş I, et al. Factor VLeiden and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol. 2001. 56:1–6.

37. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart study and 2 meta-analyses. Blood. 2002. 100:3–10.

38. Emmerich J, Poirier O, Evans A, Margues-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet. 1995. 345:321.

39. van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med. 1995. 1:185.